# Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

> **NCT02828098** · PHASE1 · COMPLETED · sponsor: **Highlight Therapeutics** · enrollment: 44 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Part 1: BO-112
- **DRUG:** Part 2: BO-112

## Key facts

- **NCT ID:** NCT02828098
- **Lead sponsor:** Highlight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828098, "Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02828098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*